What is the appropriate diagnosis and treatment for submandibular masses presenting with chronic inflammatory process and lymphoid follicles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Submandibular Masses with Chronic Inflammation and Lymphoid Follicles

Primary Diagnostic Consideration

The most critical diagnosis to establish is whether this represents Küttner tumor (chronic sclerosing sialadenitis), IgG4-related disease, or a lymphoproliferative disorder such as MALT lymphoma, as these conditions share overlapping histologic features but require fundamentally different management approaches.

Diagnostic Workup

Essential Tissue Diagnosis

  • Excisional biopsy or surgical resection is mandatory for definitive diagnosis, as fine-needle aspiration is inadequate for distinguishing between chronic inflammatory conditions and lymphoproliferative disorders 1
  • Core biopsies should only be performed if the mass is not easily accessible, though they may miss diagnostic heterogeneity 1
  • The specimen must be adequate for both formalin-fixed and fresh-frozen samples to allow immunohistochemistry and molecular studies 1

Key Histopathologic Features to Differentiate

Küttner Tumor (Chronic Sclerosing Sialadenitis):

  • Preserved lobular architecture with thickened interlobular septa
  • Dense lymphoplasmacytic infiltrate with periductal fibrosis
  • Tubular ductal structures enveloped by collagen bundles
  • Variable loss of acini with preservation of ducts 2

IgG4-Related Disease:

  • Elevated serum IgG4 levels (>135 mg/dL)
  • Tissue infiltration by IgG4-positive plasma cells (>40% of IgG-positive cells)
  • Storiform fibrosis pattern
  • Obliterative phlebitis 3

MALT Lymphoma:

  • Monoclonal B-cell population confirmed by immunoglobulin heavy-chain gene rearrangement
  • Lymphoepithelial lesions
  • Marginal zone B-cell proliferation
  • Absence of prominent plasma cell differentiation (though this can occur) 4

Inflammatory Pseudotumor:

  • Multiple nodules separated by thick fibrous bands
  • Mature plasma cells mixed with myofibroblasts in storiform pattern
  • Polyclonal hypergammaglobulinemia
  • No immunoglobulin gene rearrangement 4

Required Laboratory Studies

  • Complete blood count with differential
  • Serum IgG4 levels (reference range: 4.8-105 mg/dL) 3
  • Antinuclear antibody and rheumatoid factor to evaluate for autoimmune conditions 4
  • Serum protein electrophoresis to assess for monoclonal gammopathy
  • Toxoplasma gondii IgG antibody titers if fever preceded the mass 5

Molecular Testing

  • Polymerase chain reaction for immunoglobulin heavy-chain gene rearrangement is essential to exclude monoclonal B-cell lymphoproliferative disorders 4
  • This distinguishes reactive lymphoid hyperplasia from MALT lymphoma

Imaging Studies

  • CT scan of the neck to assess extent of disease and involvement of adjacent structures 1
  • If lymphoma is suspected based on initial biopsy, complete staging with CT chest/abdomen/pelvis and bone marrow biopsy is required 1
  • PET-CT should be performed if follicular lymphoma is confirmed to accurately stage disease before treatment decisions 1

Treatment Algorithm

For Küttner Tumor (Chronic Sclerosing Sialadenitis)

  • Observation alone is appropriate once malignancy is excluded, as this is a benign self-limited condition 2
  • Surgical excision may be performed for symptomatic relief or if malignancy cannot be definitively excluded 2

For IgG4-Related Disease

  • Corticosteroid therapy is first-line treatment
  • Rituximab for refractory cases
  • Long-term monitoring for development of malignancy, as IgG4-RD may progress to carcinoma 3

For MALT Lymphoma (if confirmed)

  • Localized disease: involved-site radiotherapy (24-30 Gy) 1
  • Advanced disease: rituximab-based chemoimmunotherapy
  • Watchful waiting for asymptomatic low-burden disease

For Follicular Lymphoma (if confirmed)

  • Stage I-II disease: involved-field radiotherapy (30-40 Gy) is the treatment of choice with curative potential 1
  • Stage III-IV disease: initiate treatment only if symptomatic (B symptoms, hematopoietic impairment, bulky disease, vital organ compression) 1
  • Asymptomatic advanced disease: watchful waiting is appropriate, as early treatment does not improve survival 1

Critical Pitfalls to Avoid

  • Never rely on fine-needle aspiration alone for diagnosis, as it cannot distinguish between reactive and neoplastic processes 1, 2
  • Do not assume benign disease based on prominent plasma cells alone, as MALT lymphoma can show plasma cell differentiation 4
  • Always exclude malignancy in patients >40 years, as metastatic disease is the most common cause of asymmetric submandibular enlargement in this age group 6
  • Obtain molecular studies even when histology appears inflammatory, as monoclonal populations can be masked by reactive changes 4
  • The prominence of lymphoid follicles and plasma cells argues against hypersensitivity pneumonitis but does not exclude lymphoproliferative disorders 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A case of adenoid cystic carcinoma associated with IgG4-related disease.

International journal of surgery case reports, 2015

Research

Toxoplasmosis submandibular lymphadenitis: Report of an unusual case with a brief review.

Journal of oral and maxillofacial pathology : JOMFP, 2018

Research

[Submandibular swelling and its differential diagnosis].

To Helleniko periodiko gia stomatike & gnathoprosopike cheirourgike, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.